X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-10-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $74.81 | -7,000 | 31,771 | -18% | -$523,648 | |||||
| D | 2026-10-13 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $350.99 | -31,027 | 9,566,326 | 0% | -$10,890,074 | |||||
| D | 2026-10-15 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $25.00 | -1,452 | 117,227 | -1% | -$36,300 | |||||
| M | 2026-10-13 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.33 | +9,569 | 955,493 | +1% | +$12,719 | |||||
| D | 2026-10-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $539.99 | -9,500 | 668,728 | -1% | -$5,129,873 | |||||
| M | 2026-10-13 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.36 | +110,000 | 1,753,000 | +7% | +$920,049 | |||||
| D | 2026-10-14 | REGN | Regeneron Pharmaceuticals, Inc. | Murphy Andrew J | Co-Chief Scientific Officer | S - Sale+OE | $772.70 | -4,147 | 52,247 | -7% | -$3,204,376 | |||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Ray Sumita | Chief Legal Compliance Officer | S - Sale | $28.05 | -1,844 | 116,701 | -2% | -$51,724 | ||||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Meluzio Michael Vincent | VP, Prin. Accounting Officer | S - Sale | $28.05 | -1,144 | 47,817 | -2% | -$32,089 | ||||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Lin Shao-Lee | CEO | S - Sale | $27.55 | -11,087 | 694,908 | -2% | -$305,490 | ||||||
| M | 2026-10-12 | PVLA | Palvella Therapeutics, Inc. | Jenkins George M | Dir | S - Sale | $130.16 | -27,500 | 146,132 | -16% | -$3,579,476 | |||||
2026-10-06 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $8.32 | -3,221 | 340,038 | -1% | -$26,798 | ||||||
2026-10-06 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $8.32 | -1,301 | 137,170 | -1% | -$10,824 | ||||||
2026-10-06 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $8.32 | -917 | 163,131 | -1% | -$7,629 | ||||||
| D | 2026-10-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $545.52 | -9,500 | 668,728 | -1% | -$5,182,414 | |||||
| D | 2026-10-14 | NRIX | Nurix Therapeutics, Inc. | Gregory Julia P | Dir | S - Sale+OE | $23.40 | -22,583 | 10,750 | -68% | -$528,528 | |||||
| AM | 2024-10-28 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | S - Sale | $1.50 | -287,845 | 13,396,000 | -2% | -$432,044 | |||||
2026-10-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $73.59 | -500 | 73,424 | -1% | -$36,795 | ||||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $28.48 | -13,692 | 617,341 | -2% | -$389,948 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $28.48 | -9,218 | 141,467 | -6% | -$262,529 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $28.48 | -8,863 | 181,487 | -5% | -$252,418 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale+OE | $28.48 | -5,245 | 115,241 | -4% | -$149,378 | |||||
2026-10-12 | LQDA | Liquidia Corp | Khindri Sanjeev | Chief Development Officer | S - Sale | $28.48 | -1,101 | 64,846 | -2% | -$31,356 | ||||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $28.48 | -18,938 | 340,148 | -5% | -$539,354 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $28.48 | -32,744 | 2,214,110 | -1% | -$932,549 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale+OE | $28.48 | -5,892 | 165,609 | -3% | -$167,804 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $28.48 | -7,301 | 177,957 | -4% | -$207,932 | |||||
| D | 2026-10-13 | RTSN | Retension Pharmaceuticals, Inc. | Keller Eric L. | CEO | P - Purchase | $12.00 | +20,800 | 464,407 | +5% | +$249,600 | |||||
| D | 2026-10-13 | RTSN | Retension Pharmaceuticals, Inc. | Berger Franklin M | Dir | P - Purchase | $12.00 | +10,000 | 22,517 | +80% | +$120,000 | |||||
| M | 2026-10-08 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.03 | +14,632 | 2,873,289 | +1% | +$29,683 | |||||
| D | 2026-10-09 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $64.26 | -192 | 105,272 | 0% | -$12,338 | |||||
2026-10-12 | LYEL | Lyell Immunopharma, Inc. | Aguirre Jarrad Mattieu | Chief Medical Officer | S - Sale | $8.63 | -422 | 19,857 | -2% | -$3,642 | ||||||
2026-10-08 | OCUL | Ocular Therapeutix, Inc | Anderman Todd | GC | S - Sale | $7.29 | -11,984 | 140,484 | -8% | -$87,363 | ||||||
| D | 2026-10-12 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $80.60 | -9,999 | 14,219 | -41% | -$805,889 | |||||
| D | 2026-10-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $550.70 | -9,500 | 668,728 | -1% | -$5,231,666 | |||||
| D | 2026-10-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $544.94 | -9,500 | 668,728 | -1% | -$5,176,936 | |||||
| D | 2026-10-12 | ZVRA | Zevra Therapeutics, Inc. | McFarlane Neil F. | Pres, CEO | S - Sale+OE | $11.25 | -20,000 | 417,225 | -5% | -$224,948 | |||||
| D | 2026-10-12 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $62.88 | -7,500 | 282,710 | -3% | -$471,600 | |||||
| D | 2026-10-08 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale+OE | $36.32 | -6,000 | 62,284 | -9% | -$217,920 | |||||
| D | 2026-10-09 | ZYME | Zymeworks Inc. | Schayowitz Adam | EVP, Head of R, D | S - Sale+OE | $25.85 | -13,832 | 23,205 | -37% | -$357,557 | |||||
2026-10-07 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $63.39 | -2,500 | 1,457,360 | 0% | -$158,480 | ||||||
| D | 2026-10-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $534.31 | -9,500 | 668,728 | -1% | -$5,075,919 | |||||
| D | 2026-10-08 | URGN | Urogen Pharma Ltd. | Degnan Chris | CFO | S - Sale+OE | $36.69 | -2,202 | 4,561 | -33% | -$80,791 | |||||
| M | 2026-10-07 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.47 | +215,000 | 1,643,000 | +15% | +$1,821,054 | |||||
| D | 2026-10-06 | IDYA | Ideaya Biosciences, Inc. | Hata Yujiro S | Pres, CEO | S - Sale+OE | $37.41 | -26,338 | 690,695 | -4% | -$985,397 | |||||
| M | 2026-10-06 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.33 | +10,903 | 945,924 | +1% | +$14,484 | |||||
| D | 2026-10-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $548.95 | -9,500 | 668,728 | -1% | -$5,215,015 | |||||
| M | 2026-10-06 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $31.68 | -4,522 | 554,703 | -1% | -$143,273 | |||||
| A | 2026-10-05 | BCYC | Bicycle Therapeutics Plc | Perry Jennifer Scott | COO | S - Sale | $3.76 | -356 | 89,602 | 0% | -$1,339 | |||||
2026-10-06 | JAZZ | Jazz Pharmaceuticals Plc | Gala Renee D | Pres, CEO | S - Sale | $236.40 | -2,000 | 141,394 | -1% | -$472,800 | ||||||
| DM | 2026-10-05 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $64.06 | -2,073 | 105,272 | -2% | -$132,791 | |||||
2026-10-05 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | GC | S - Sale | $1.99 | -294 | 81,715 | 0% | -$585 | ||||||
| D | 2026-10-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $538.68 | -9,500 | 668,728 | -1% | -$5,117,412 | |||||
2026-10-05 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $27.13 | -235,477 | 104,570 | -69% | -$6,387,596 | ||||||
2026-10-05 | AMLX | Amylyx Pharmaceuticals, Inc. | Milne George M Jr | Dir | S - Sale | $27.70 | -30,000 | 782,881 | -4% | -$830,904 | ||||||
2026-10-07 | EBS | Emergent Biosolutions Inc. | Degolyer Donald W | Dir | S - Sale | $7.09 | -17,800 | 111,921 | -14% | -$126,202 | ||||||
| D | 2026-10-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $541.64 | -9,500 | 668,728 | -1% | -$5,145,537 | |||||
| D | 2026-10-06 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $61.38 | -3,500 | 153,902 | -2% | -$214,830 | |||||
2026-10-02 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $16.00 | +2,500 | 27,000 | +10% | +$40,000 | ||||||
2026-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Supran Bryan | EVP, CLO, Secretary | S - Sale | $226.88 | -1,758 | 12,807 | -12% | -$398,855 | ||||||
2026-10-02 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.57 | +100,000 | 1,428,000 | +8% | +$857,240 | ||||||
| D | 2026-10-01 | RDHL | Redhill Biopharma Ltd. | Raday Gilead | COO | S - Sale+OE | $0.00 | -14,310,000 | 176,910,000 | -7% | -$1,431 | |||||
| D | 2026-10-02 | CORT | Corcept Therapeutics Inc | Vieira Roberto Wandenkolk | Pres, Oncology | S - Sale+OE | $116.10 | -8,333 | 3,946 | -68% | -$967,448 | |||||
| DM | 2026-10-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $116.07 | -10,000 | 5,683 | -64% | -$1,160,731 | |||||
| DM | 2026-10-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $116.26 | -25,000 | 119,655 | -17% | -$2,906,601 | |||||
2026-10-01 | BLTE | Belite Bio, Inc | Scholl Hendrik Peter | Chief Medical Officer | S - Sale | $165.32 | -500 | 14,500 | -3% | -$82,659 | ||||||
| M | 2026-10-01 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.05 | +60,490 | 2,858,657 | +2% | +$123,819 | |||||
| D | 2026-10-01 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | S - Sale+OE | $36.10 | -17,750 | 14,954 | -54% | -$640,861 | |||||
| D | 2026-10-01 | MNPR | Monopar Therapeutics | Starr Christopher M | Dir | S - Sale+OE | $78.50 | -8,400 | 15,053 | -36% | -$659,387 | |||||
| D | 2026-10-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $24.47 | -27,000 | 115,743 | -19% | -$660,796 | |||||
2026-10-05 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $57.10 | -4,126 | 19,020 | -18% | -$235,595 | ||||||
| M | 2026-10-01 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.33 | +42,920 | 935,021 | +5% | +$57,080 | |||||
| D | 2026-10-01 | ELVN | Enliven Therapeutics, Inc. | Garland J. Scott | Dir | S - Sale+OE | $46.67 | -13,000 | 0 | -100% | -$606,719 | |||||
| D | 2026-10-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $549.37 | -9,500 | 668,728 | -1% | -$5,219,015 | |||||
2026-10-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $230.33 | -6,000 | 345,875 | -2% | -$1,381,980 | ||||||
2026-10-01 | RMTI | Rockwell Medical, Inc. | Strobeck Mark | Pres, CEO | S - Sale | $8.42 | -1,000 | 61,349 | -2% | -$8,420 | ||||||
2026-10-01 | EBS | Emergent Biosolutions Inc. | Williams Paul Anthony | SVP, Products Business | S - Sale | $6.53 | -3,000 | 156,098 | -2% | -$19,590 | ||||||
| D | 2026-10-01 | SYRE | Spyre Therapeutics, Inc. | King-Jones Heidy | See Remarks | S - Sale+OE | $91.03 | -28,933 | 2,845 | -91% | -$2,633,902 | |||||
2026-10-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $92.01 | -15,000 | 537,540 | -3% | -$1,380,105 | ||||||
| DM | 2026-09-30 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $90.47 | -25,000 | 79,762 | -24% | -$2,261,831 | |||||
| D | 2026-10-01 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale+OE | $83.62 | -25,000 | 923,128 | -3% | -$2,090,593 | |||||
2026-09-30 | IRD | Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | S - Sale | $4.96 | -556,000 | 3,236,171 | -15% | -$2,755,981 | ||||||
2026-10-02 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $41.03 | -2,034 | 221,388 | -1% | -$83,455 | ||||||
2026-09-30 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $25.46 | -75,000 | 528,621 | -12% | -$1,909,665 | ||||||
| D | 2026-10-01 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale+OE | $12.91 | -6,700 | 241,772 | -3% | -$86,524 | |||||
| D | 2026-10-01 | ANAB | Anaptysbio, Inc | Renton Hollings | Dir | S - Sale+OE | $49.87 | -5,000 | 10,995 | -31% | -$249,372 | |||||
| D | 2026-09-30 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $36.62 | -200,000 | 1,599,154 | -11% | -$7,324,000 | |||||
2026-10-02 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale | $26.33 | -627 | 20,598 | -3% | -$16,509 | ||||||
2026-10-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $26.16 | -1,051 | 19,059 | -5% | -$27,494 | ||||||
| D | 2026-10-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $23.19 | -5,786 | 9,110 | -39% | -$134,149 | |||||
| D | 2026-09-30 | PTCT | Ptc Therapeutics, Inc. | Steele Glenn Jr Md Phd | Dir | S - Sale+OE | $65.16 | -12,000 | 22,500 | -35% | -$781,920 | |||||
2026-10-01 | ORMP | Oramed Pharmaceuticals Inc. | Gabay Avraham | CFO | S - Sale | $4.51 | -20,000 | 861,076 | -2% | -$90,200 | ||||||
2026-10-01 | ORMP | Oramed Pharmaceuticals Inc. | Hexter Joshua | COO, CBO | S - Sale | $4.51 | -30,000 | 1,328,130 | -2% | -$135,330 | ||||||
2026-10-01 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $8.00 | -44,121 | 652,712 | -6% | -$352,968 | ||||||
2026-10-01 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $8.00 | -2,566 | 123,781 | -2% | -$20,528 | ||||||
2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $9.41 | -5,000 | 1,351,053 | 0% | -$47,037 | ||||||
2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $9.41 | -15,000 | 1,624,208 | -1% | -$141,120 | ||||||
2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $9.41 | -16,666 | 1,111,130 | -1% | -$156,792 | ||||||
2026-09-30 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $375.00 | -1,115 | 311,324 | 0% | -$418,125 | ||||||
| D | 2026-10-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $576.47 | -9,500 | 668,728 | -1% | -$5,476,462 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |